PPS expands API manufacturing footprint with $55m investment

PPS expands API manufacturing footprint with $55m investment
Credit: Shutterstock.com/ Dmitry Kalinovsky

Contract manufacturer Piramal Pharma Solutions (PPS) is expanding its API manufacturing capabilities with a $55 million investment across its sites in North American and Asia.

Part of the investment will be ploughed into new bleeding edge multipurpose plants to support PPS current pipeline of late-stage programmes.

The manufacturer will also expand its potency footprint at its Riverview, Michigan plant while augmenting early development capabilities out of Ennore, India through additions of GMP kilo labs and a pilot plant.

To serve its European biotech customers better, PPS said it will add early development capabilities in both drug substance and drug product out of its Morpeth, UK facility.